Childhood obesity and related long-term effects are serious public health problems, but not
all children with obesity do well in treatment. This study will test a new combination of
family-based behavioral treatment (FBT) with a drug intervention using a glucagon-like
peptide-1 receptor agonist (GLP-1RA) exenatide once weekly extended-release (ExQW, Bydureon®)
in order to improve obesity intervention outcomes in 10-12-year-old children.